BB Biotech hat auch im 3. Quartal seinen Anteil an Radius Health um 9% ausgebaut
www.bbbiotech.ch/...f/Zwischenberichte/2017/BION_Q32017_DE.pdf
Negativer Trend Vote für Abaloparatide-SC Zulassung in Europa
www.streetinsider.com/Corporate+News//...ide-SC/14428625.html
Radius Health meldet Zahlen für Q2/18
investors.radiuspharm.com/news-releases/...-2018-financial-and
Earnings Call Slides
seekingalpha.com/article/...8-q2-results-earnings-call-slides
Radius Health meldet Ergebnisse für Q3/18
"Full-year TYMLOS net revenues expected to be $95m to $98m for 2018 and $155m to $175m for 2019. Year-end cash, cash equivalents and investments anticipated to exceed $220m for 2018 and $100m for 2019"
ir.radiuspharm.com/news-releases/...018-operating-results-and
Radius Health meldet Zahlen für 2018
ir.radiuspharm.com/news-releases/...uarter-and-full-year-2018
Radius Health meldet Zahlen für Q2/19
ir.radiuspharm.com/news-releases/...er-2019-operating-results
Zahlen für 2019
"Recruitment of three Phase 3 studies is advancing and expected to be completed in 2020, with anticipated data read-outs in the second half of 2021"
ir.radiuspharm.com/news-releases/...uarter-and-full-year-2019
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 70 | Radius Health | mora77 | Vassago | 31.01.23 15:09 |